---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-017331"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:25:02.046297+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics promotes Kaitlin Kestenberg to COO and SVP, Compliance

## Summary
- Kestenberg promoted from SVP, Compliance & Project Operations to COO and SVP, Compliance, effective April 1, 2024.
- Base salary of $460,000; annual target bonus of 50% of base salary.
- Granted options for 300,328 shares and 192,320 RSUs, each vesting over four years.
- Severance includes 12 months salary (or 15 months plus 1.5x bonus upon change of control) plus COBRA.
- Kestenberg has been with ADMA since 2011; prior roles at Acorda Therapeutics and Merck.

## SEC filing metadata
- accession: 0001140361-24-017331
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/0001140361-24-017331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/ef20025617_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-017331
- JSON: https://secwatch.observer/filing/0001140361-24-017331.json
- Plain text: https://secwatch.observer/filing/0001140361-24-017331.txt

## Key facts
- Executive change
  Kaitlin Kestenberg changed role as Chief Operating Officer and Senior Vice President, Compliance at ADMA BIOLOGICS, INC..
  - Action: promoted
  - Role: Chief Operating Officer and Senior Vice President, Compliance
  source text: Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/0001140361-24-017331-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.